Literature DB >> 15192052

CpG oligodeoxynucleotides enhance FcgammaRI-mediated cross presentation by dendritic cells.

Lisette Bevaart1, Heidi H Van Ojik, Amanda W Sun, Timothy H Sulahian, Jeanette H W Leusen, George J Weiner, Jan G J Van De Winkel, Martine J Van Vugt.   

Abstract

Dendritic cells (DC) can trigger naive CD8(+) T cell responses by their capacity to cross-present exogenous antigens via the major histocompatibility complex class I pathway. The myeloid class I IgG receptor, FcgammaRI (CD64), is expressed on DC, and in vivo targeting of antigens to FcgammaRI induces strong humoral and cellular immune responses. We studied the capacity of human FcgammaRI (hFcgammaRI) to facilitate DC-mediated cross presentation and T cell activation, and assessed the effect of CpG oligodeoxynucleotides on this process. We generated hFcgammaRI expressing immature DC from hFcgammaRI transgenic and immature DC from non-transgenic mice. Antigens were targeted to Fcgamma receptors as ovalbumin immune complexes, or selectively to hFcgammaRI via ovalbumin-CD64 mAb fusion proteins. Co-incubation of immature DC with CpG ODN led to markedly increased MHC class I presentation of FcgammaR-targeted antigens. When OVA was selectively targeted to hFcgammaRI, few differences were observed between Tg and NTg DC. However, upon co-incubation with CpG ODN, hFcgammaRI-triggered cross presentation was enhanced. These results document the capacity of hFcgammaRI on DC to trigger cross presentation via MHC class I upon co-culture with CpG ODN.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15192052     DOI: 10.1093/intimm/dxh110

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  5 in total

Review 1.  Cross-presentation of IgG-containing immune complexes.

Authors:  Kristi Baker; Timo Rath; Wayne I Lencer; Edda Fiebiger; Richard S Blumberg
Journal:  Cell Mol Life Sci       Date:  2012-07-31       Impact factor: 9.261

Review 2.  Monoclonal antibody mechanisms of action in cancer.

Authors:  George J Weiner
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

3.  The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden.

Authors:  Peter Boross; J H Marco Jansen; Simone de Haij; Frank J Beurskens; Cees E van der Poel; Lisette Bevaart; Maaike Nederend; Josée Golay; Jan G J van de Winkel; Paul W H I Parren; Jeanette H W Leusen
Journal:  Haematologica       Date:  2011-08-31       Impact factor: 9.941

4.  Cytokine-associated neutrophil extracellular traps and antinuclear antibodies in Plasmodium falciparum infected children under six years of age.

Authors:  Virginia S Baker; Godwin E Imade; Norman B Molta; Pallavi Tawde; Sunday D Pam; Michael O Obadofin; Soloman A Sagay; Daniel Z Egah; Daniel Iya; Bangmboye B Afolabi; Murray Baker; Karen Ford; Robert Ford; Kenneth H Roux; Thomas Cs Keller
Journal:  Malar J       Date:  2008-02-29       Impact factor: 2.979

5.  Liposomal TLR9 Agonist Combined with TLR2 Agonist-Fused Antigen Can Modulate Tumor Microenvironment through Dendritic Cells.

Authors:  Kuan-Yin Shen; Hsin-Yu Liu; Wan-Lun Yan; Chiao-Chieh Wu; Ming-Hui Lee; Chih-Hsing Leng; Shih-Jen Liu
Journal:  Cancers (Basel)       Date:  2020-03-28       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.